Publications

Detailed Information

Neurotoxic syndrome developed after taking sertraline and risperidone

DC Field Value Language
dc.contributor.authorKim, J. M.-
dc.contributor.authorLee, S. T.-
dc.contributor.authorSong, E. C.-
dc.contributor.authorJung, K. H.-
dc.contributor.authorSinn, D. I.-
dc.contributor.authorChung, H.-
dc.contributor.authorChu, K.-
dc.contributor.authorKim, M.-
dc.date.accessioned2009-12-24T07:46:24Z-
dc.date.available2009-12-24T07:46:24Z-
dc.date.issued2007-09-01-
dc.identifier.citationJ Clin Neurol. 2007 Sep;3(3):165-7. Epub 2007 Sep 20.en
dc.identifier.issn1738-6586 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19513287-
dc.identifier.urihttps://hdl.handle.net/10371/22345-
dc.description.abstractNeuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.en
dc.language.isoen-
dc.titleNeurotoxic syndrome developed after taking sertraline and risperidoneen
dc.typeArticleen
dc.contributor.AlternativeAuthor김정민-
dc.contributor.AlternativeAuthor이순태-
dc.contributor.AlternativeAuthor송은철-
dc.contributor.AlternativeAuthor정건화-
dc.contributor.AlternativeAuthor신동인-
dc.contributor.AlternativeAuthor정학재-
dc.contributor.AlternativeAuthor주건-
dc.contributor.AlternativeAuthor김만호-
dc.identifier.doi10.3988/jcn.2007.3.3.165-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share